Ancient Trees, Dwindling in the Wild, Thrive on Sacred Ground
The Putuo hornbeam, a hardy tree that thrives in the damp air by the East China Sea, could be easily overlooked by visitors to the Huiji Temple on an island in the Zhejiang Province.
The tree has an unremarkable appearance: spotty bark, small stature and serrated leaves with veins as neatly spaced as notebook lines. But its status is singular. As far as conservationists can tell, no other mature specimen of its species is alive in the wild.
The holdout on the island, Mount Putuo, has been there for about two centuries. And according to a study published Wednesday in the journal Current Biology, its setting may have been its salvation.
The study found that religious sites in eastern China have become refuges for old, ancient and endangered trees. Since the early years of the Common Era, Buddhist and Taoist temples have sheltered plants that otherwise struggled to find a foothold, including at least eight species that now exist nowhere else on earth.
'This form of biodiversity conservation, rooted in cultural and traditional practices, has proven to be remarkably resilient, persisting even in the face of modern civilization and rapid economic development,' said Zhiyao Tang, a professor of ecology at Peking University and one of the study's authors.
The trees survived at religious sites in part because they were planted and cultivated there. The report noted that Buddhism and Taoism emphasize spiritual association with plants and the temples tended to be left undisturbed, shielding the areas from deforestation.
Want all of The Times? Subscribe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
2 days ago
- Medscape
Novel GLP-1 Agonist Promotes Safe and Effective Weight Loss
Ecnoglutide, a novel glucagon-like peptide-1 (GLP-1) receptor agonist, was significantly more effective than placebo for inducing weight loss in adults with overweight or obesity, based on data from more than 600 individuals, results of the SLIMMER trial showed. In addition, ecnoglutide significantly improved other key cardiometabolic risk factors including waist circumference, blood pressure, lipid profile, A1c, fasting glucose, insulin level, and uric acid, while concurrently reducing liver fat content, said study author Linong Ji, MD, of Peking University People's Hospital, Beijing, China. "These benefits position ecnoglutide as a compelling therapeutic strategy for managing clinical obesity, especially in the context of metabolic dysfunction and associated steatotic liver disease (MASLD)," he noted. The results of the phase 3 randomized trial were presented here at the American Diabetes Association (ADA) 85th Scientific Sessions and simultaneously published in The Lancet Diabetes & Endocrinology . The new drug is distinct from other GLP-1 receptor agonists in its ability to selectively induce production of cyclic adenosine monophosphate (cAMP). Unlike unbiased GLP-1 therapies, ecnoglutide selectively activates cAMP signaling pathways while minimizing β-arrestin recruitment, which may explain its enhanced effectiveness for body weight reduction and sustained metabolic effects, Ji said in an interview. Weight Loss at All Doses The researchers randomized 664 overweight and obese Chinese adults to a weekly dose of 1.2 mg, 1.8 mg, or 2.4 mg of ecnoglutide or to placebo. The coprimary endpoints were percentage change in body weight and proportion of individuals with a reduction of 5% or more in body weight after 40 weeks. The study population included adults aged 18-75 years with overweight or obesity, defined as a BMI of 28 kg/m² or higher, or 24 kg/m² or higher with at least one weight-related comorbidity (prediabetes, hypertension, hyperlipidemia, MASLD, obstructive sleep apnea syndrome, or weight-bearing joint pain), but without type 1 or 2 diabetes. The mean age of participants was 34.2 years, and half were female. Individuals in the ecnoglutide group had an average body weight loss of 9.1%, 10.9%, and 13.2% from baseline at 40 weeks at doses of 1.2 mg, 1.8 mg, and 2.4 mg, respectively, which was significantly greater at all dose levels than placebo (0.1%) ( P < 0.0001 vs placebo for all doses). In addition, significantly more patients in the ecnoglutide groups lost at least 5% of their body weight at week 40 compared to the placebo group (77%, 84%, 87%, and 16% in the 1.2-mg, 1.8-mg, 2.4-mg, and placebo groups, respectively). A key secondary efficacy endpoint was the percentage of individuals who achieved a body weight loss of at least 5% after 48 weeks; 78% to 93% of participants across the ecnoglutide groups achieved this endpoint, with the greatest changes at the higher doses. Ten individuals across the ecnoglutide groups discontinued the medication because of adverse events, the most common of which were mild-to-moderate gastrointestinal events. Treatment-emergent adverse events occurred in 93% of participants in each of the ecnoglutide groups and in 84% of the placebo group. Clinical Takeaways and Next Steps "Ecnoglutide not only represents a viable competitor in the GLP-1 analog market but also stands out with its potential to address the nonresponse limitations in obesity treatment while providing holistic metabolic benefits," Ji told Medscape Medical News . At least 10% of weight-loss patients fail to achieve clinically significant weight loss of at least 5%, he explained. Possible reasons for the lack of success include genetic polymorphisms, metabolic heterogeneity, treatment compliance, or differential receptor sensitivity, he noted. "Providing alternative treatment options with a high response rate is crucial for individuals nonresponsive to existing therapies," he said. The trial results mark a milestone in obesity therapeutics and are a significant achievement in weight management. "After 48 weeks of treatment, ecnoglutide achieved a 15.4% weight reduction, with 92.8% of patients attaining clinically meaningful weight loss," he emphasized. "Considering the high potency of ecnoglutide" and the safety data, "it might serve as a viable option for individuals who do not achieve sufficient weight reduction with existing GLP-1 receptor agonists at their approved doses or need to achieve a better reduction in body weight," he added. "I am confident and optimistic that we'll see more personalized treatment regimens for obesity." Looking ahead, patients in the ecnoglutide 1.8-mg and 2.4-mg groups continued to have weight loss at week 48 without reaching a plateau, indicating that even greater weight loss might be possible with extended ecnoglutide treatment in studies of longer duration, Ji told Medscape Medical News . "To confer the added clinical advantage, a study comparing the clinical effects of a biased GLP-1 analog with those of a pharmacokinetically-matched but balanced GLP-1 analog would be needed," he said. In an accompanying editorial, Tricia M-M Tan, PhD, of Imperial College, London, UK, wrote: "The development of biased GLP-1 receptor agonists has been met with enthusiasm from the pharmaceutical industry, but does this design feature really confer any added clinical advantage?" She agreed with Ji that a comparative study of "a biased GLP-1 analog with those of a pharmacokinetically-matched but balanced GLP-1 analog" is needed. "Only then will the clinical role of this design feature be clear," she said. However, "the clinical results from ecnoglutide are likely to be generalizable to other populations," given that the effects of GLP-1 analogs are similar when tested in patients of various ethnicities, she said, adding this may increase the global availability of GLP-1 treatments. Refining Molecules to Enhance Efficacy, Reduce Side Effects Although current therapies represent potent, effective options for obesity-modifying treatment, they have limitations, with heterogeneity of responses in terms of potency and tolerability, said Andrew Kraftson, MD, a specialist in endocrinology and internal medicine at the University of Michigan, Ann Arbor, in an interview. "Ecnoglutide continues the trend to refine these molecules to enhance efficacy and reduce side effects," he said. "When these types of peptides interact with cells, they activate certain receptors and generate a signal cascade that promotes the desired effects. However, the less specific the 'message', the less potent the signal. Additionally, side effects can be a result of the less-controlled message," he noted. As with tirzepatide, ecnoglutide was developed to produce a "biased" signal with the intent to provide greater control of the signal/message to increase the odds of weight control and reduce the odds of side effects, he explained. Although the current study was not a head-to-head comparison with other incretin mimetics, the similarity in weight loss efficacy to tirzepatide, a dual GLP-1/glucagon insulinotropic peptide agonist (GIP), was interesting and supports the biasing effect of the molecular manipulation as an effective strategy to refine incretin therapy, Kraftson told Medscape Medical News . From a clinical standpoint, the trend towards refining weight management therapy will benefit patients by expanding their options, said Kraftson. "It may also help us address the observed heterogeneity in clinical response we see in our patients and bring us closer to personalized medicine," he said. The current study's limitations, as acknowledged by the researchers, include the relatively short time period, small sample size, and lack of head-to-head comparison, said Kraftson. Additionally, the study differs from clinical practice in its dose escalation, he said. In practice, "we are not trying to get patients to a certain dose, we are trying to find the lowest, most tolerable, and sufficiently effective dose to achieve health goals; therefore, we may determine that dose titration needs to happen more slowly and/or that a low(er) dose may be sufficiently effective," he told Medscape Medical News . "The adverse event data for common gastrointestinal issues could potentially be better in clinical practice if mitigation strategies are employed," he said. "I would like to see future studies that go beyond finding the relative efficacy of doses to reporting on effective strategies for patient-dose matching."
Yahoo
3 days ago
- Yahoo
'Shocking' find could change the way Aussies visit the beach
For 200 years, there has been speculation that swimmers could be tormented by more than one species of bluebottle jellyfish. It turns out there are at least four, including one in Australia that has a 'prominent nose'. 'We were shocked, because we assumed they were all the same species," Griffith University marine ecologist Professor Kylie Pitt said. Until recently, studying these notorious jellyfish has been a challenge because they're hard to keep in captivity, and when they wash up on the beach they disintegrate quickly. Speaking with Yahoo News, Pitt explained the game-changer has been advances in DNA sequencing. 'With our paper, we used the most powerful method, whole genome sequencing, so it's entire DNA has been sampled,' she said. 'By combining the DNA with morphology, we've got the strongest evidence possible for separating out the species.' The discovery is likely to have a direct impact on Aussie swimmers because it could help researchers better understand jellyfish behaviour and predict when they'll swarm towards beaches. Pitt was part of an international research effort by Yale University, University of New South Wales and Griffith University that sequenced the genomes of 151 jellyfish from around the world and published their findings in the journal Current Biology. A key finding of the study that the notorious Portuguese man o' war is only found in the Atlantic and is a completely separate species from Australian bluebottles. 'For a long time, people have said they're much bigger over there and the venom is much more potent,' Pitt said. 'Now we know that the potency of their venom might differ.' Related: 😳 Swimmer's painful encounter with deadly creature on Queensland island The existence of three newly described species, Physalia physalis, Physalia utriculus and Physalia megalista, had been proposed in the 18th and 19th Centuries, but the idea was later dismissed. The researchers also identified a fourth species Physalia minuta that had never been described before. 'The one that really stands out is Physalia megalista because it has a really pronounced nose,' Pitt said. It's also believed there are several distinct subpopulations shaped by regional winds and ocean currents. This new knowledge about bluebottles will have a real-world impact for swimmers, as there could be differences with the venom of Australian species too. It will also help support an investigation into jellyfish behaviour that's funded by the Australian Research Council. 🌏 Secret hidden beneath Australia's 'most important' parcel of land 👙 Tourists oblivious to disturbing scene 500m off sunny Aussie beach 📸 Confronting picture showcases state of Aussie wildlife on world stage Pitt explained a PhD student is working to understand how winds and currents move the bluebottles towards beaches, as well as how they move in the water. 'Bluebottles can actually erect their float or lay it down, depending upon what the wind conditions are. And they can also expand and or extend and contract their tentacles, which might act a little bit like a sea anchor, so there might be a bit more of a drag,' she said. 'Now we know there are at least three species in Australia she may need to look at their behavioural differences.' Love Australia's weird and wonderful environment? 🐊🦘😳 Get our new newsletter showcasing the week's best stories.
Medscape
5 days ago
- Medscape
Are Sports Drink Just Colorful Delusions?
Every gym in America is awash in neon. The rainbow array of sports drinks promises to transform weekend warriors into athletic dynamos. For decades, these beverages have occupied a curious space in American consumer culture, somewhere between medicine and marketing, between science and snake oil. Now comes a study showing sports drinks might improve athletic performance. Sort of. Researchers from Peking University in Beijing, China, recently presented a poster at the American Society for Nutrition (ASN) 2025 Annual Meeting in Orlando, Florida, from what appears to be a rigorous experiment: 23 trained adults who consumed a multi-ingredient sports drink performed 15% better during high-intensity exercise than when they drank a placebo beverage. The drink contained a blend of macronutrients and micronutrients: Sugar for immediate energy, taurine and lysine as amino acids, inositol for cellular function, caffeine as a stimulant, and niacin and vitamins B6 and B12 to help metabolize food into energy. The patients experienced less fatigue, maintained higher energy levels, and showed improved metabolic markers that suggested their bodies were preserving muscle protein during exercise, according to the researchers. 'I wouldn't say the findings are shocking or excitingly novel,' said Andrew Jagim, PhD, director of Sports Medicine Research at Mayo Clinic Health System, in La Crosse, Wisconsin. The participants were already trained athletes performing structured, 100-minute exercise sessions, a far cry from the typical American's relationship with physical activity. According to the US Department of Health and Human Services, adults should spend at least 150 min/wk doing aerobic exercise, but only two thirds of Americans meet this guideline. This disconnect between laboratory conditions and real life gets to the heart of what Stella Volpe, PhD, MS, head of the Department of Human Nutrition, Foods, and Exercise at Virginia Tech University in Blacksburg, Virginia, calls the fundamental question: 'For the average person who might be exercising 30 minutes a day, likely they don't need something like this. Likely they are fine with just water.' Jose Antonio, PhD, MS, the CEO of the International Society of Sports Nutrition and professor of health and human performance at Nova Southeastern University in Fort Lauderdale, Florida, concurs. 'Traditionally, sports drinks have been shown for decades to improve performance, reduce fatigue, etc.,' Antonio said. 'It often depends on what the ingredients are. We already know caffeine is effective. The most important components of this sports drink are, of course, the fluid itself, but [also] the sugar and caffeine. The rest of it has a minor effect.' Sports drinks can be dense in calories. A 16-oz bottle of AMP Energy, for example, is 220 calories per serving compared with 155 for a 12-oz serving of Coca-Cola. For Jagim, the question becomes one of benefits and costs: 'Are those extra calories in that drink really worth what they're chasing in terms of just burning more calories during the workout?' 'When I train or race, I focus on two things [in a sports drink]: Sugar and caffeine,' he added. 'The rest is ok, but for most, it doesn't matter. Don't trip over dollars to pick up pennies.' But a psychological dimension complicates the purely nutritional calculus. Volpe, a professional athlete on the USA Masters field hockey team, said she will 'hydrate better if I drink more.' Consuming a beverage that tastes better than water can improve overall fluid intake. If a sports drink gets someone to stay properly hydrated during exercise, as long as they do not have diabetes or are trying to lose weight, the modest caloric cost might be worth paying. 'I'd say go for it,' she said. Jagim and Antonio agree valuable future research would be testing different treatment groups using different versions of the same drink. 'Then you'd be able to answer that question of which ingredient is the more important one here,' Jagim said. 'Is it the carbohydrate or the caffeine? Or is it truly, when we combine them, we get that synergistic benefit, where they collectively help each other make you feel better and perform better?' Antonio, Jagim, and Volpe reported having no relevant financial conflicts of interest.
